BioWorld - Thursday, January 1, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: BioWorld 2025 Year in ReviewBreaking News: BioWorld MedTech 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sector

BioWorld Science
BioWorld Science RSS Feed RSS

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow
Immuno-oncology

NI-3201, an example of effective PD-L1-dependent CD28 costimulation

Jan. 21, 2025
Cancer immunotherapy has represented a significant advancement in cancer treatment; however, many patients experience relapse or develop resistance to this treatment. Bispecific antibodies that selectively engage T-cell costimulatory molecules have emerged as a novel therapeutic strategy to overcome the limitations of immunotherapy.
Read More
Steadying hand while reaching for glass
Neurology/psychiatric

Dual-action compound shows promise for Parkinson’s motor and nonmotor symptoms

Jan. 21, 2025
Parkinson’s disease, characterized by progressive dopamine neuron loss, leads to motor deficits such as bradykinesia and rigidity, as well as nonmotor symptoms like cognitive decline and depression. While L-DOPA alleviates motor symptoms, long-term use often results in side effects, including motor fluctuations and dyskinesias, as well as nonmotor (psychotic-like) side effects.
Read More
Red blood cells, DNA
Hematologic

Yoltech advances gene editing therapy into clinic for β-thalassemia

Jan. 21, 2025
Yoltech Therapeutics Co. Ltd. has advanced YOLT-204 into the clinic for the treatment of transfusion-dependent β-thalassemia (TDT). If successful, YOLT-204 may provide an off-the-shelf curative treatment for TDT patients without conditioning chemotherapy and hematopoietic stem cell transplantation.
Read More
Cancer

SIAIS-562055, a SOS1 PROTAC with activity in models of KRAS-mutant tumors and BCR-ABL-positive leukemia

Jan. 21, 2025
Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor (GEF) in KRAS-driven tumors, and it also functions as a downstream node protein of BCR-ABL, suggesting its critical role in the pathogenesis of chronic myeloid leukemia (CML). Investigators at Shanghaitech University have reported the discovery and preclinical characterization of a novel potent SOS1 proteolysis targeting chimera (PROTAC) – SIAIS-562055 – being developed as an anticancer agent.
Read More
Illustration of cobra in front of protein structures
Substance use & poisoning

An antidote to cobra venom designed with AI

Jan. 21, 2025
By Mar de Miguel
Following Nobel Prize-winning chemist David Baker’s recipe for cooking an antidote to cobra venom using artificial intelligence (AI) could be faster and more effective than currently available methods. The ingredients and steps can be found in a new study published by the University of Washington (UW) scientist in collaboration with the Technical University of Denmark. They are ready for the next steps in preclinical trials.
Read More
Neurology/psychiatric

Nanjing Reju Therapeutics discovers new TRADD inhibitors

Jan. 20, 2025
Nanjing Reju Therapeutics Inc. has described tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) inhibitors reported to be useful for the treatment of inflammatory-related disorders and cell necrosis-related apoptosis diseases.
Read More